ABCL: AbCellera Biologics Inc.
Performance
ABCL +219.69%
Watchlist
Select an item
Summary
ABCL at a glance
ABCL returned +219.69% over the past year and -3.69% a year over five years. Its worst drop in that year was -40.09%, smaller than 37% of stocks on Redstone, and its Sharpe ratio of 1.74 beats 96% of stocks on Redstone. It pays no dividends.
Current Drawdown
-15.65%
Rolling Volatility
86.79%
Actions
Metrics
Risk Indicators
Alpha123.74%
Beta2.50x
Sharpe1.74
Sortino3.01
Omega1.36
Calmar5.48
Martin8.51
Profile
About ABCL
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $4.1B
- Listed
- Dec 2020
- Employees
- 562
- Headquarters
- Vancouver, A1
- Website
- abcellera.com
Comparisons